Analyzing Regenxbio (RGNX) and Its Rivals
Regenxbio (NASDAQ: RGNX) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Regenxbio to similar companies based on the strength of its institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
Institutional and Insider Ownership
68.7% of Regenxbio shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.0% of Regenxbio shares are owned by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Regenxbio has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, Regenxbio’s peers have a beta of 0.65, suggesting that their average share price is 35% less volatile than the S&P 500.
This is a summary of current ratings and price targets for Regenxbio and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Regenxbio currently has a consensus price target of $43.17, indicating a potential upside of 22.63%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.75%. Given Regenxbio’s peers higher possible upside, analysts clearly believe Regenxbio has less favorable growth aspects than its peers.
This table compares Regenxbio and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Regenxbio and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Regenxbio||$4.59 million||-$62.96 million||-13.04|
|Regenxbio Competitors||$290.27 million||$35.99 million||60.37|
Regenxbio’s peers have higher revenue and earnings than Regenxbio. Regenxbio is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Regenxbio peers beat Regenxbio on 8 of the 13 factors compared.
Regenxbio Company Profile
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.